Biocon Secures Pebrilzo Launch Dates; Shares Fall 0.94%

Mumbai, October 14: Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, securing licensed launch dates for Pebrilzo® (pertuzumab), its biosimilar to Perjeta®. The agreement resolves pending disputes between the companies across the US, Canada and other jurisdictions, while establishing a timeline for the product’s planned market entry in several regions.

According to the company statement filed with the BSE and National Stock Exchange of India on October 14, 2026, the settlement covers pending patent disputes between Biocon and Genentech, including proceedings in the US, Canada and other jurisdictions.

The agreement allows Biocon to launch Pebrilzo in the European Union and the UK in the first quarter of calendar year 2027. The permitted launch date in the US is the third quarter of calendar year 2028. In other Rest of the World markets, launches are permitted during calendar years 2026 to 2028, or earlier in certain circumstances.

Biocon said the other terms of the agreement are confidential. The company also noted that product launches in individual countries and regions remain subject to regulatory approval.

Stock Market Snapshot

The Biocon share price stood at ₹347.70 as of 10:03:58 AM IST on October 14, 2026, according to the market data provided. The stock was down ₹3.30, or 0.94%, at that time.

The price movement was recorded on the day the company disclosed the settlement and launch timelines. The available data does not establish that the announcement alone drove the decline.

Market participants tracking the Biocon share price will be watching how the licensed launch schedule translates into commercial availability, subject to regulatory clearances and the terms of the agreement.

Pebrilzo Targets HER2-Positive Breast Cancer

Pebrilzo is a biosimilar medicine containing pertuzumab, a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2). The treatment is used for HER2-positive breast cancer across multiple disease stages.

The settlement provides a defined launch framework for Biocon’s product across key markets, although commercialisation remains dependent on the applicable regulatory requirements. The company has not disclosed the financial terms of the agreement.

Conclusion: Settlement Establishes a Regional Launch Timeline

The agreement with Genentech resolves pending patent disputes and sets licensed launch dates for Pebrilzo across the European Union, the UK, the US and other markets. The earliest stated launch window is Q1 2027 in the European Union and UK, followed by Q3 2028 in the US.

The financial terms remain confidential, and regulatory approval is still required for launches in each relevant market. Biocon’s October 14 share-price snapshot showed a decline of 0.94% to ₹347.70 as of 10:03:58 AM IST.

Source:

• https://www.nseindia.com/get-quote/equity/BIOCON/Biocon-Limited
• https://nsearchives.nseindia.com/corporate/BIOCON_14102026082951_SEIntimation.pdf